Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-221613 · Präparat HOS-216856
Co-administration with CYP3A- metabolised corticosteroids is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid effects. Alternative corticosteroids which are less dependent on CYP3A metabolism, e.g. beclomethasone for intranasal or inhalational use, should be considered, particularly for long-term use. kinase inhibitors ↑R406 active metabolite of Concomitant use of fostamatinib fostamatinib fostamatinib with EVOTAZ may increase the plasma concentration of R406, the The mechanism of interaction is active metabolite of fostamatinib. CYP3A4 inhibition by atazanavir Monitor for toxicities of R406 and/or cobicistat. exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required. ANTIDEPRESSANTS Other antidepressants: trazodone Plasma concentrations of If trazodone is co-administered trazodone may be increased with EVOTAZ, the combination when co-administered with should be used with caution and a EVOTAZ. lower dose of trazodone should be considered. The mechanism of interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trazodone (HOS-086251) beclomethasone (HOS-086334) fostamatinib (HOS-086224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 920993d9fb6b8c2eeea2b17a8fd504a1718093214fd8201ba0f2077524356dbb · Zeichen 64455–67200 im Abschnitt